跳至主要内容
临床试验/NCT02906176
NCT02906176已完成1 期

A Clinical Trail to Investigate the Influence of SLCO2B1 Polymorphism on the Pharmacokinetic Characteristics of Voriconazole in CYP2C19 Poor Metabolizers

Seoul National University Hospital1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2016年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
12
试验地点
1
主要终点
Pharmacokinetic outcome - Maximum plasma concentration (Cmax)

研究概览

简要总结

A clinical trail to investigate the influence of SLCO2B1 polymorphism on the pharmacokinetic characteristics of voriconazole in CYP2C19 poor metabolizers

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None

入排标准

年龄范围
20 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy male volunteer who is a CYP2C19 Poor metabolizer with rs3781727 SNP wild or variant genotype

排除标准

  • History of clinically significant respiratory, cardiovascular, renal, hepatic, hematologic, neurological disorder

研究组 & 干预措施

SLCO2B1 wild type

Experimental

Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h (Day 1) - washout period - Vfend (voriconazole) 200 mg tablet once (Day 8)

干预措施: Vfend (voriconazole) intravenous infusion (Drug)

SLCO2B1 wild type

Experimental

Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h (Day 1) - washout period - Vfend (voriconazole) 200 mg tablet once (Day 8)

干预措施: Vfend (voriconazole) tablet (Drug)

SLCO2B1 variant

Experimental

Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h (Day 1) - washout period - Vfend (voriconazole) 200 mg tablet once (Day 8)

干预措施: Vfend (voriconazole) intravenous infusion (Drug)

SLCO2B1 variant

Experimental

Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h (Day 1) - washout period - Vfend (voriconazole) 200 mg tablet once (Day 8)

干预措施: Vfend (voriconazole) tablet (Drug)

结局指标

主要结局

Pharmacokinetic outcome - Maximum plasma concentration (Cmax)

时间窗: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose

Pharmacokinetic outcome - Area under the plasma concentration versus time curve (AUC)

时间窗: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours post-dose

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

SeungHwan Lee

Assistant Professor

Seoul National University Hospital

研究点 (1)

Loading locations...

相似试验

Influence of SLCO2B1 Polymorphism on the PK of... | 临床试验